On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Stocks To Buy Now

Blog


PaxMedica Inc. (NASDAQ: PXMD) Releases Compelling Video:  Progress Report on ASD and Hope for the Future

  • Autism Spectrum Disorder (“ASD”) has seen a staggering fourfold increase in the United States over the past two decades
  • PaxMedica proudly stands as the sole publicly traded U.S. company singularly dedicated to addressing the challenges posed by Autism
  • Our pioneering lead product, PAX-101, has shown significant promise in alleviating core Autism symptoms during early trials
  • In 2024, we’re poised to submit a New Drug Application (“NDA”) for PAX-101 to treat Human African Trypanosomiasis (“HAT”), a rare disease also known as African Sleeping Sickness, as part of the Neglected Rare Tropical Disease Program
  • With NDA approval, we anticipate the potential to secure a valuable Priority Review Voucher (“PRV”) that could expedite our journey toward FDA recognition for Autism treatment
  • Vigorous preparations are underway for clinical trials of PAX-101 in Autism, marking a significant step forward in our mission

In a powerful and informative video message, PaxMedica’s (NASDAQ: PXMD) Chairman and CEO, Howard Weisman, shares a progress report on the critical work being done to address the rising prevalence of Autism Spectrum Disorder (“ASD”) in the United States. This disorder has seen a fourfold increase over the past two decades, underscoring the urgency of PaxMedica’s mission.

PaxMedica stands alone as the only publicly traded company in the U.S. with an unwavering focus on ASD. Weisman highlights the dedication and commitment of the entire PaxMedica team to confront the unique challenges of autism head-on.

Click Here to View the Video 

Weisman further emphasizes the company’s groundbreaking lead product, PAX-101. Early trials of PAX-101 have shown remarkable promise in reducing the core symptoms of Autism, offering newfound hope to countless families affected by this condition.

Looking to the future, PaxMedica has ambitious plans. The company is preparing for an NDA submission of PAX-101 for the treatment of Human African Trypanosomiasis (“HAT”), also known as African Sleeping Sickness, scheduled for 2024. This effort falls under the Neglected Rare Tropical Disease Program, and if approved, could pave the way for PaxMedica to receive a highly valuable Priority Review Voucher (“PRV”), expediting its path to gaining FDA approval for Autism indication.

As PaxMedica prepares for clinical trials of PAX-101 for Autism, Weisman and his team are unwavering in their commitment to bring about transformative change for individuals and families affected by ASD. With optimism and dedication, PaxMedica is focused on delivering innovative solutions and a brighter future for those touched by autism.

For more information, visit the company’s website at www.PaxMedica.com.

NOTE TO INVESTORS: The latest news and updates relating to PXMD are available in the company’s newsroom at https://ibn.fm/PXMD

From Our Blog

DGE’s 3rd Transparency & Aggregate Spend Summit to Discuss Ways to Improve Compliance and Efficiency of HCP Spend Reporting

May 20, 2024

DGE invites professionals and executives from pharma, biotech, and medical device companies, to attend the 3rd Transparency & Aggregate Spend Conference being held on June 3-4, 2024. The event is being organized by DGE in Philadelphia. With the growing need of transparency in compliance programs, the 3rd Transparency and Aggregate Spend Summit addresses the complex […]

Rotate your device 90° to view site.